Clinical Trial

Efficacy Anda Safety of Etoricoxib With Betamethasone for the Treatment of Acute Gout Arthritis

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
Phase III longitudinal, multicenter, randomized, double-blind clinical trial. The aim of this study is to evaluate the efficacy and safety of the Fixed-Dose Combination of Etoricoxib/Betamethasone Versus Etoricoxib in Patients With Acute Gouty Arthritis
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-03-03.
Trial Details
NCT Number NCT06863701
Lead Sponsor Laboratorios Silanes S.A. de C.V.
Conditions Gout Arthritis, Gout Attack
Enrollment 72 participants
Start Date 2025-01-27
Primary Completion 2026-12-31 (estimated)
Study Completion 2027-01-31 (estimated)
Updated on ClinicalTrials.gov 2025-04-03